HomeCompareLZAGF vs HDV

LZAGF vs HDV: Dividend Comparison 2026

LZAGF yields 1.10% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LZAGF wins by $20.2K in total portfolio value· pulled ahead in Year 5
10 years
LZAGF
LZAGF
● Live price
1.10%
Share price
$650.29
Annual div
$7.14
5Y div CAGR
45.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$8,733.09
Full LZAGF calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.39
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$352.73
Full HDV calculator →

Portfolio growth — LZAGF vs HDV

📍 LZAGF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGFHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGF + HDV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGF pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGF
Annual income on $10K today (after 15% tax)
$93.36/yr
After 10yr DRIP, annual income (after tax)
$7,423.13/yr
HDV
Annual income on $10K today (after 15% tax)
$248.52/yr
After 10yr DRIP, annual income (after tax)
$299.82/yr
At 15% tax rate, LZAGF beats the other by $7,123.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGF + HDV for your $10,000?

LZAGF: 50%HDV: 50%
100% HDV50/50100% LZAGF
Portfolio after 10yr
$34.4K
Annual income
$4,542.91/yr
Blended yield
13.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LZAGF right now

LZAGF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
7/9
HDV
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGF buys
0
HDV buys
0
No recent congressional trades found for LZAGF or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGFHDV
Forward yield1.10%2.92%
Annual dividend / share$7.14$3.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR45.9%0%
Portfolio after 10y$44.5K$24.3K
Annual income after 10y$8,733.09$352.73
Total dividends collected$22.1K$3.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LZAGF vs HDV ($10,000, DRIP)

YearLZAGF PortfolioLZAGF Income/yrHDV PortfolioHDV Income/yrGap
1$10,860$160.25$11,002$292.38$142.00HDV
2$11,858$237.31$12,084$300.36$226.00HDV
3$13,041$353.30$13,250$308.02$209.00HDV
4$14,484$529.82$14,506$315.35$22.00HDV
5← crossover$16,300$802.36$15,858$322.35+$442.00LZAGF
6$18,672$1,231.24$17,313$329.04+$1.4KLZAGF
7$21,903$1,923.20$18,878$335.42+$3.0KLZAGF
8$26,512$3,076.05$20,560$341.49+$6.0KLZAGF
9$33,445$5,077.02$22,367$347.25+$11.1KLZAGF
10$44,519$8,733.09$24,307$352.73+$20.2KLZAGF

LZAGF vs HDV: Complete Analysis 2026

LZAGFStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGF Calculator →

HDVETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this LZAGF vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGF vs SCHDLZAGF vs JEPILZAGF vs OLZAGF vs KOLZAGF vs MAINLZAGF vs VYMLZAGF vs DVYLZAGF vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.